Biotech News

Altimmune to Participate in Upcoming Investor Conferences

Altimmune (ALT)Altimmune2026-05-27 12:30 ESTConference / presentation

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

2026 Jefferies Global Healthcare Conference Thursday, June 4, 2026 Fireside chat at 12:50 p.m. ET New York, NY

Goldman Sachs 47 th Annual Global Healthcare Conference Wednesday, June 10, 2026 Fireside chat at 8:00 a.m. ET Miami Beach, FL

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .

Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X

Investor Contact: Luis Sanay, CFA Vice President, Investor Relations ir@altimmune.com

Media Contact: Real Chemistry altimmune@realchemistry.com

Altimmune

Altimmune is a metabolic and infectious-disease biotech focused on obesity and liver disease as well as immune applications. Its current story is heavily tied to cardiometabolic upside.

Recent company news

ALTAltimmune2026-07-28 11:00 EST

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

ALTAltimmune2026-05-28 15:00 EST

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

ALTAltimmune2026-05-27 12:30 EST